Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24971854 | 0.90 | SMN1; SMN2 (0.39) | MC4RCHRM2CHRM1ADRA2ADRD1 | |
| SCHEMBL20661653 | 0.87 | — | — | |
| SCHEMBL3416020 | 0.87 | — | — | |
| SCHEMBL7142061 | 0.87 | CYP2D6 (0.32) | CYP2D6 | |
| SCHEMBL179841 | 0.87 | CYP2D6 (0.32) | CYP2D6 | |
| SCHEMBL16556858 | 0.79 | CHRM2 (0.39) | MC4RCHRM2CHRM1ADRA2ADRD1 | |
| SCHEMBL23980869 | 0.79 | CHRNA7 (0.37) | KCNH2CYP2D6HRH3KDM4EALDH1A1 | |
| SCHEMBL22171348 | 0.78 | MC4R (0.39) | MC4RCHRM2CHRM1ADRA2ADRD1 | |
| SCHEMBL23015892 | 0.78 | MC4R (0.39) | MC4RCHRM2CHRM1ADRA2ADRD1 | |
| SCHEMBL22184337 | 0.78 | MC4R (0.39) | MC4RCHRM2CHRM1ADRA2ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117915958-A | Dendritic structures as non-viral vectors in gene delivery | 蒂巴生物技术有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-1092737-B1 | Catalyst composition for the production of a polyurethane resin, and method for producing a polyurethane resin | TOSOH CORP (JP) | 2003-09-24 | — | — | EP | claimed |
| US-6596663-B1 | Reacting a polyol with an organic polyisocyanate in the presence of a diamine catalyst and, if necessary, a blowing agent, a surfactant, a cross-linking agent | TOSOH CORPORATION (JP) | 2003-07-22 | — | — | US | claimed |
| EP-1092737-A2 | Catalyst composition for the production of a polyurethane resin, and method for producing a polyurethane resin | Tosoh Corporation (JP) | 2001-04-18 | — | — | EP | claimed |
| US-5262534-A | Process for the preparation of nonaromatic cyclic nitrogen-containing compounds | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1993-11-16 | — | — | US | claimed |
| EP-0476783-A1 | Processes for the preparation of nonaromatic N,N,N-trisubstituted nitrogen-containing compounds | UNION CARBIDE CHEMICALS AND PLASTICS COMPANY, INC. (US) | 1992-03-25 | — | — | EP | claimed |
| CN-121591615-B | Memantine derivative and synthesis method and application thereof | Shandong Xinhua Pharmaceutical Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-119912036-A | Application of 4-methyl-1-piperazine ethylamine as nitrification inhibitor and method for inhibiting nitrification | 湖北华宸生态环境有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-117915958-A | Dendritic structures as non-viral vectors in gene delivery | 蒂巴生物技术有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4223761-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20220332695-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2022-10-20 | — | — | US | disclosed |
| WO-2022089219-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2022-05-05 | — | — | WO | disclosed |
| EP-3990112-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RTI International (US) | 2022-05-04 | — | — | EP | disclosed |
| US-6596663-B1 | Reacting a polyol with an organic polyisocyanate in the presence of a diamine catalyst and, if necessary, a blowing agent, a surfactant, a cross-linking agent | TOSOH CORPORATION (JP) | 2003-07-22 | — | — | US | disclosed |
| EP-1312630-A1 | Process for the production of flexible polyurethane foams | Tosoh Corporation (JP) | 2003-05-21 | — | — | EP | disclosed |
| EP-1092737-A2 | Catalyst composition for the production of a polyurethane resin, and method for producing a polyurethane resin | Tosoh Corporation (JP) | 2001-04-18 | — | — | EP | disclosed |
| EP-0612324-A1 | PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1994-08-31 | — | — | EP | disclosed |
| US-5262534-A | Process for the preparation of nonaromatic cyclic nitrogen-containing compounds | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1993-11-16 | — | — | US | disclosed |
| WO-1993009136-A1 | PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1993-05-13 | — | — | WO | disclosed |
| EP-0476783-A1 | Processes for the preparation of nonaromatic N,N,N-trisubstituted nitrogen-containing compounds | UNION CARBIDE CHEMICALS AND PLASTICS COMPANY, INC. (US) | 1992-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332695-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR119 | MC4R 224/4885CHRM2 702/4885CHRM1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.